Encoded Therapeutics secures $275M to advance Dravet syndrome gene therapy
Encoded Therapeutics has raised $275 million in a Series F round led by GV and an undisclosed healthcare investor. The company focuses on precision genetic medicines, and the new funds will support its lead program for Dravet syndrome, a severe form of epilepsy. The financing will help advance clinical development and potential regulatory submission.
The financing round, led by GV and an unnamed healthcare investor, provides Encoded Therapeutics with substantial capital. This funding is earmarked specifically for the company's lead therapeutic program.
That program addresses Dravet syndrome, a severe epilepsy disorder. The capital will support ongoing clinical trials and help prepare for a potential regulatory filing, moving the therapy closer to patients.
This investment could accelerate the availability of a targeted genetic therapy for individuals living with Dravet syndrome, a condition that often leads to lifelong, debilitating seizures. If clinical trials succeed, patients and caregivers may gain a more precise treatment option, potentially reducing the burden of current broad-spectrum medications. However, regulatory hurdles and long-term safety data may remain critical factors. The broader field of precision medicine could also benefit from this validation of gene-based approaches for rare neurological disorders.